Li Ju, Zhu Yan
Department of Hematology, Southwest Hospital, Army Medical University, Chongqing 400038, China.
Stem Cell Investig. 2019 Dec 12;6:42. doi: 10.21037/sci.2019.10.05. eCollection 2019.
Hematopoietic stem cell transplantation has been applied to treat the hematologic malignancies since the 1980s. However, allogenic transplantation has inherent complications such as graft-versus-host disease and graft failure. Autologous transplantation has become more and more popular because of its lower transplant-related mortality. This study was performed to analyze the possible prognostic factors for myeloma patients post stem cell transplantation.
Patients' information was collected by history review and follow-up through the phone call. Kaplan-Meier was used to exhibit overall survival (OS) and progression-free survival (PFS). Univariate and multivariate analyses were performed using Cox proportional hazards model. A P<0.05 is considered statistically significant.
Thirty patients with multiple myeloma were included in this study, 7 of them died because of myeloma relapse and myeloma-associated complications. The average survival time was 29.8 months and the median follow-up was 25.1 months. The 1-year OS and PFS were 93.3% and 90.0%, respectively. Both the 3-year OS and PFS were 76.7%. In a variety of factors, improved renal function showed a good effect on the outcome of transplantation.
To prevent cancer relapse after autologous transplantation, it is of great significance to achieve a complete remission prior to the transplantation.
自20世纪80年代以来，造血干细胞移植已被应用于治疗血液系统恶性肿瘤。然而，异基因移植存在诸如移植物抗宿主病和移植物失败等固有并发症。自体移植因其较低的移植相关死亡率而越来越受欢迎。本研究旨在分析骨髓瘤患者干细胞移植后的可能预后因素。
通过病史回顾和电话随访收集患者信息。采用Kaplan-Meier法展示总生存期（OS）和无进展生存期（PFS）。使用Cox比例风险模型进行单因素和多因素分析。P<0.05被认为具有统计学意义。
本研究纳入30例多发性骨髓瘤患者，其中7例因骨髓瘤复发和骨髓瘤相关并发症死亡。平均生存时间为29.8个月，中位随访时间为25.1个月。1年总生存率和无进展生存率分别为93.3%和90.0%。3年总生存率和无进展生存率均为76.7%。在各种因素中，肾功能改善对移植结局显示出良好影响。
为预防自体移植后癌症复发，在移植前实现完全缓解具有重要意义。
